Menu
Scroll to Top
Locations
New York, NY, USA
Stage
Seed
founded in
2021
Pyrojas is at the forefront of personalized cancer immunotherapy, utilizing its innovative Pyro Cells platform to create rapid-response, autologous cancer vaccines. This technology addresses the complexities of tumor heterogeneity and immunosuppressive environments, offering an antigen-agnostic approach that targets a wide range of tumor antigens. With a breakthrough automated manufacturing system, personalized vaccines can be produced within 24 hours at the surgical site, ensuring timely and patient-specific treatment. The Pyro TIMER platform further enhances CAR-T and TCR-T cell therapies, improving T cell persistence and effectiveness against solid tumors and refractory cancers. With validated preclinical success and licensing opportunities, Pyrojas is positioned as a transformative player in the cancer treatment landscape.
Something looks off?